Strategy

As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.

As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop.

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

We leap tall buildings to bring you the definitive guide to the world's top pharmaceutical companies.

When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.

As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.

In an effort to realign its sales division to reflect the current pharma environment-smaller, faster, better-Johnson & Johnson is trimming its sales force.

A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements.

Just two months after the purchase of Wyeth, Pfizer breaks its research division into two-one for large molecules and vaccines, and another for small molecules-with Wyeth and Pfizer execs at the helms.

From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations.

"Best Pharma not Big Pharma" is Merck Serono head Elmar Schnee's business philosophy. He tells Pharm Exec Europe how the Swiss-based company aims to achieve that goal, and points out the current political obstacles.

Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.

Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.

After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression.

Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety-and the regulators who enforce it.

Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.

Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year.

GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts.

Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.

Convert future revenue into present value with alternative approaches to access capital.

The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.

For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists.

Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good?

Long-standing Nycomed CEO Håkan Björklund tells Pharm Exec Europe how the company is looking to new products, and new territories, to combat the patent expiry of its biggest product.

"Test and treat" strategies aren't just for new-to-market drugs anymore.

Every industry has a life cycle, and pharma's has just entered its competitive stage. Here's how to prepare.

We know what you're thinking: new president, rotten economy, patent cliff. Do you feel Evel? Well, do you?

Pharm Exec talks with James Christian, head of security at Novartis, to learn more about what the company is doing to protect its supply chain and stop counterfeiters

Two years ago, an internal Merck survey revealed that its basic research operation was "every flavor of what you don't want." Today the company is in the midst of implementing a new strategy that groups scientists at sites dedicated to particular clinical areas. VP Kathleen Metters explains why - and how.

At its annual business briefing, Merck surprised analysts with the announcement that it would be launching a new business in the biologics sector in an effort to create generic biotech drugs.